Schett, Georg

The Pathogenesis of Rheumatoid Arthritis

McInnes, I. B., & Schett, G. (2011) · New England Journal of Medicine

Rheumatoid Arthritis Research and TherapiesAutoimmune and Inflammatory Disorders Research

Cited by 5,514

Trial of tocilizumab in giant-cell arteritis

Stone, J. H., Tuckwell, K., Dimonaco, S., Klearman, M., Aringer, M., Blockmans, D., Brouwer, E., Cid, M. C., Dasgupta, B., Rech, J., et al. (2017) · New England Journal of Medicine

Vasculitis and related conditionsRheumatoid Arthritis Research and Therapies

Cited by 1,386

Aggregated neutrophil extracellular traps limit inflammation by degrading cytokines and chemokines

Schauer, C., Janko, C., Munoz, L. E., Zhao, Y., Kienhöfer, D., Frey, B., Lell, M., Manger, B., Rech, J., Naschberger, E., et al. (2014) · Nature Medicine

Neutrophil, Myeloperoxidase and Oxidative MechanismsInflammation biomarkers and pathways

Cited by 998

Bone erosion in rheumatoid arthritis: mechanisms, diagnosis and treatment

Schett, G., & Gravallese, E. (2012) · Nature Reviews Rheumatology

Rheumatoid Arthritis Research and TherapiesBone Metabolism and Diseases

Cited by 947

Activation of canonical Wnt signalling is required for TGF-β-mediated fibrosis

Akhmetshina, A., Palumbo, K., Dees, C., Bergmann, C., Venalis, P., Zerr, P., Horn, A., Kireva, T., Beyer, C., Zwerina, J., et al. (2012) · Nature Communications

TGF-β signaling in diseasesWnt/β-catenin signaling in development and cancer

Cited by 843

Short-chain fatty acids regulate systemic bone mass and protect from pathological bone loss

Lucas, S., Omata, Y., Hofmann, J., Böttcher, M., Iljazovic, A., Sarter, K., Albrecht, O., Schulz, O., Krishnacoumar, B., Krönke, G., et al. (2018) · Nature Communications

Bone Metabolism and DiseasesGut microbiota and health

Cited by 815

Osteoclasts are essential for TNF-α-mediated joint destruction.

Redlich, K., Hayer, S., Ricci, R., David, J.-P., Tohidast-Akrad, M., Kollias, G., Steiner, G., Smolen, J. S., Wagner, E. F., & Schett, G. (2002) · Journal of Clinical Investigation

Rheumatoid Arthritis Research and TherapiesBone Metabolism and Diseases

Cited by 474

How Cytokine Networks Fuel Inflammation: Toward a cytokine-based disease taxonomy

Schett, G., Elewaut, D., McInnes, I. B., Dayer, J.-M., & Neurath, M. F. (2013) · Nature Medicine

Cytokine Signaling Pathways and InteractionsPsoriasis: Treatment and Pathogenesis

Cited by 406

The gut-bone axis: How bacterial metabolites bridge the distance

Zaiss, M. M., Jones, R. M., Schett, G., & Pacifici, R. (2019) · Journal of Clinical Investigation

Gut microbiota and healthBone Metabolism and Diseases

Cited by 403

Imatinib mesylate reduces production of extracellular matrix and prevents development of experimental dermal fibrosis

Distler, J. H. W., Jüngel, A., Huber, L. C., Schulze‐Horsel, U., Zwerina, J., Gay, R. E., Michel, B. A., Hauser, T., Schett, G., Gay, S., et al. (2007) · Arthritis & Rheumatism

Systemic Sclerosis and Related DiseasesDupuytren's Contracture and Treatments

Cited by 383

Activation of STAT3 integrates common profibrotic pathways to promote fibroblast activation and tissue fibrosis

Chakraborty, D., Šumová, B., Mallano, T., Chen, C.-W., Distler, A., Bergmann, C., Ludolph, I., Horch, R. E., Gelse, K., Ramming, A., et al. (2017) · Nature Communications

Systemic Sclerosis and Related DiseasesCytokine Signaling Pathways and Interactions

Cited by 356

Effects of inflammatory and anti‐inflammatory cytokines on the bone

Schett, G. (2011) · European Journal of Clinical Investigation

Bone Metabolism and DiseasesRheumatoid Arthritis Research and Therapies

Cited by 292

Tumor necrosis factor α-mediated joint destruction is inhibited by targeting osteoclasts with osteoprotegerin.

Redlich, K., Hayer, S., Maier, A., Dunstan, C. R., Tohidast‐Akrad, M., Lang, S., Türk, B., Pietschmann, P., Woloszczuk, W., Haralambous, S., et al. (2002) · Arthritis & Rheumatism

Rheumatoid Arthritis Research and TherapiesBone Metabolism and Diseases

Cited by 285

Platelet-derived serotonin links vascular disease and tissue fibrosis

Dees, C., Akhmetshina, A., Zerr, P., Reich, N., Palumbo, K., Horn, A., Jüngel, A., Beyer, C., Krönke, G., Zwerina, J., et al. (2011) · Journal of Experimental Medicine

Systemic Sclerosis and Related DiseasesTGF-β signaling in diseases

Cited by 266

Inhibition of interleukin-6 receptor directly blocks osteoclast formation in vitro and in vivo

Axmann, R., Böhm, C., Krönke, G., Zwerina, J., Smolen, J., & Schett, G. (2009) · Arthritis & Rheumatism

Bone Metabolism and DiseasesRheumatoid Arthritis Research and Therapies

Cited by 263

IκB kinase (IKK)β, but not IKKα, is a critical mediator of osteoclast survival and is required for inflammation-induced bone loss

Ruocco, M. G., Maeda, S., Park, J. M., Lawrence, T., Hsu, L.-C., Cao, Y., Schett, G., Wagner, E. F., & Karin, M. (2005) · The Journal of Experimental Medicine

Bone Metabolism and DiseasesNF-κB Signaling Pathways

Cited by 252

Inflammatory osteolysis: A conspiracy against bone

Mbalaviele, G., Novack, D. V., Schett, G., & Teitelbaum, S. L. (2017) · Journal of Clinical Investigation

Bone Metabolism and DiseasesOsteomyelitis and Bone Disorders Research

Cited by 251

β-catenin is a central mediator of pro-fibrotic Wnt signaling in systemic sclerosis

Beyer, C., Schramm, A., Akhmetshina, A., Dees, C., Kireva, T., Gelse, K., Sonnylal, S., de Crombrugghe, B., Taketo, M. M., Distler, O., et al. (2012) · Annals of the Rheumatic Diseases

Systemic Sclerosis and Related DiseasesTGF-β signaling in diseases

Cited by 203

Mobile Health Usage, Preferences, Barriers, and eHealth Literacy in Rheumatology: Patient Survey Study

Knitza, J., Simon, D., Lambrecht, A., Raab, C., Tascilar, K., Hagen, M., Kleyer, A., Bayat, S., Derungs, A., Amft, O., et al. (2020) · JMIR mHealth and uHealth

Mobile Health and mHealth ApplicationsHealth Literacy and Information Accessibility

Cited by 201

Nintedanib inhibits fibroblast activation and ameliorates fibrosis in preclinical models of systemic sclerosis

Huang, J., Beyer, C., Palumbo-Zerr, K., Zhang, Y., Ramming, A., Distler, A., Gelse, K., Distler, O., Schett, G., Wollin, L., et al. (2016) · Annals of the Rheumatic Diseases

Systemic Sclerosis and Related DiseasesDupuytren's Contracture and Treatments

Cited by 196

Neutrophil Extracellular Traps Initiate Gallstone Formation

Muñoz, L. E., Boeltz, S., Bilyy, R., Schauer, C., Mahajan, A., Widulin, N., Grüneboom, A., Herrmann, I., Boada, E., Rauh, M., et al. (2019) · Immunity

Neutrophil, Myeloperoxidase and Oxidative MechanismsGallbladder and Bile Duct Disorders

Cited by 192

COVID-19 revisiting inflammatory pathways of arthritis

Schett, G., Manger, B., Simon, D., & Caporali, R. (2020) · Nature Reviews Rheumatology

COVID-19 Clinical Research StudiesRheumatoid Arthritis Research and Therapies

Cited by 191

Osteocyte necrosis triggers osteoclast-mediated bone loss through macrophage-inducible C-type lectin

Andreev, D., Liu, M., Weidner, D., Kachler, K., Faas, M., Grüneboom, A., Schlötzer-Schrehardt, U., Muñoz, L. E., Steffen, U., Grötsch, B., et al. (2020) · Journal of Clinical Investigation

Bone Metabolism and DiseasesImmune Response and Inflammation

Cited by 188

Dual inhibition of c-abl and PDGF receptor signaling by dasatinib and nilotinib for the treatment of dermal fibrosis

Akhmetshina, A., Dees, C., Pileckyte, M., Maurer, B., Axmann, R., Jüngel, A., Zwerina, J., Gay, S., Schett, G., Distler, O., et al. (2008) · The FASEB Journal

Systemic Sclerosis and Related DiseasesDupuytren's Contracture and Treatments

Cited by 187